Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose

Catherine J Reynolds, Corinna Pade, Joseph M Gibbons, David K Butler, Ashley D Otter, Katia Menacho, Marianna Fontana, Angelique Smit, Jane E Sackville-West, Teresa Cutino-Moguel, Mala K Maini, Benjamin Chain, Mahdad Noursadeghi, UK COVIDsortium Immune Correlates Network, Tim Brooks, Amanda Semper, Charlotte Manisty, Thomas A Treibel, James C Moon, UK COVIDsortium Investigators, Ana M Valdes, Áine McKnight, Daniel M Altmann, Rosemary Boyton, Hakam Abbass, Mashael Alfarih, Zoe Alldis, Daniel M Altmann, Oliver E Amin, Mervyn Andiapen, Jessica Artico, João B Augusto, Georgina L Baca, Sasha N L Bailey, Anish N Bhuva, Alex Boulter, Ruth Bowles, Rosemary J Boyton, Olivia V Bracken, Ben O'Brien, Tim Brooks, Natalie Bullock, David K Butler, Gabriella Captur, Nicola Champion, Carmen Chan, Aneesh Chandran, Jorge Couto de Sousa, Xose Couto-Parada, Teresa Cutino-Moguel, Rhodri H Davies, Brooke Douglas, Cecilia Di Genova, Keenan Dieobi-Anene, Mariana O Diniz, Anaya Ellis, Karen Feehan, Malcolm Finlay, Marianna Fontana, Nasim Forooghi, Joseph M Gibbons, Derek Gilroy, Matt Hamblin, Gabrielle Harker, Jacqueline Hewson, Lauren M Hickling, Aroon D Hingorani, Lee Howes, Ivie Itua, Victor Jardim, Wing-Yiu Jason Lee, Melaniepetra Jensen, Jessica Jones, Meleri Jones, George Joy, Vikas Kapil, Hibba Kurdi, Jonathan Lambourne, Kai-Min Lin, Sarah Louth, Mala K Maini, Vineela Mandadapu, Charlotte Manisty, Áine McKnight, Katia Menacho, Celina Mfuko, Oliver Mitchelmore, Christopher Moon, James C Moon, Sam M Murray, Mahdad Noursadeghi, Ashley Otter, Corinna Pade, Susana Palma, Ruth Parker, Kush Patel, Babita Pawarova, Steffen E Petersen, Brian Piniera, Franziska P Pieper, Lisa Rannigan, Alicja Rapala, Catherine J Reynolds, Amy Richards, Matthew Robathan, Joshua Rosenheim, Genine Sambile, Nathalie M Schmidt, Amanda Semper, Andreas Seraphim, Mihaela Simion, Angelique Smit, Michelle Sugimoto, Leo Swadling, Stephen Taylor, Nigel Temperton, Stephen Thomas, George D Thornton, Thomas A Treibel, Art Tucker, Jessry Veerapen, Mohit Vijayakumar, Sophie Welch, Theresa Wodehouse, Lucinda Wynne, Dan Zahedi, Benjamin Chain, Catherine J Reynolds, Corinna Pade, Joseph M Gibbons, David K Butler, Ashley D Otter, Katia Menacho, Marianna Fontana, Angelique Smit, Jane E Sackville-West, Teresa Cutino-Moguel, Mala K Maini, Benjamin Chain, Mahdad Noursadeghi, UK COVIDsortium Immune Correlates Network, Tim Brooks, Amanda Semper, Charlotte Manisty, Thomas A Treibel, James C Moon, UK COVIDsortium Investigators, Ana M Valdes, Áine McKnight, Daniel M Altmann, Rosemary Boyton, Hakam Abbass, Mashael Alfarih, Zoe Alldis, Daniel M Altmann, Oliver E Amin, Mervyn Andiapen, Jessica Artico, João B Augusto, Georgina L Baca, Sasha N L Bailey, Anish N Bhuva, Alex Boulter, Ruth Bowles, Rosemary J Boyton, Olivia V Bracken, Ben O'Brien, Tim Brooks, Natalie Bullock, David K Butler, Gabriella Captur, Nicola Champion, Carmen Chan, Aneesh Chandran, Jorge Couto de Sousa, Xose Couto-Parada, Teresa Cutino-Moguel, Rhodri H Davies, Brooke Douglas, Cecilia Di Genova, Keenan Dieobi-Anene, Mariana O Diniz, Anaya Ellis, Karen Feehan, Malcolm Finlay, Marianna Fontana, Nasim Forooghi, Joseph M Gibbons, Derek Gilroy, Matt Hamblin, Gabrielle Harker, Jacqueline Hewson, Lauren M Hickling, Aroon D Hingorani, Lee Howes, Ivie Itua, Victor Jardim, Wing-Yiu Jason Lee, Melaniepetra Jensen, Jessica Jones, Meleri Jones, George Joy, Vikas Kapil, Hibba Kurdi, Jonathan Lambourne, Kai-Min Lin, Sarah Louth, Mala K Maini, Vineela Mandadapu, Charlotte Manisty, Áine McKnight, Katia Menacho, Celina Mfuko, Oliver Mitchelmore, Christopher Moon, James C Moon, Sam M Murray, Mahdad Noursadeghi, Ashley Otter, Corinna Pade, Susana Palma, Ruth Parker, Kush Patel, Babita Pawarova, Steffen E Petersen, Brian Piniera, Franziska P Pieper, Lisa Rannigan, Alicja Rapala, Catherine J Reynolds, Amy Richards, Matthew Robathan, Joshua Rosenheim, Genine Sambile, Nathalie M Schmidt, Amanda Semper, Andreas Seraphim, Mihaela Simion, Angelique Smit, Michelle Sugimoto, Leo Swadling, Stephen Taylor, Nigel Temperton, Stephen Thomas, George D Thornton, Thomas A Treibel, Art Tucker, Jessry Veerapen, Mohit Vijayakumar, Sophie Welch, Theresa Wodehouse, Lucinda Wynne, Dan Zahedi, Benjamin Chain

Abstract

SARS-CoV-2 vaccine rollout has coincided with the spread of variants of concern. We investigated if single dose vaccination, with or without prior infection, confers cross protective immunity to variants. We analyzed T and B cell responses after first dose vaccination with the Pfizer/BioNTech mRNA vaccine BNT162b2 in healthcare workers (HCW) followed longitudinally, with or without prior Wuhan-Hu-1 SARS-CoV-2 infection. After one dose, individuals with prior infection showed enhanced T cell immunity, antibody secreting memory B cell response to spike and neutralizing antibodies effective against B.1.1.7 and B.1.351. By comparison, HCW receiving one vaccine dose without prior infection showed reduced immunity against variants. B.1.1.7 and B.1.351 spike mutations resulted in increased, abrogated or unchanged T cell responses depending on human leukocyte antigen (HLA) polymorphisms. Single dose vaccination with BNT162b2 in the context of prior infection with a heterologous variant substantially enhances neutralizing antibody responses against variants.

Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution License 4.0 (CC BY).

Figures

Fig. 1. Impact of prior natural infection…
Fig. 1. Impact of prior natural infection with SARS-CoV-2 during the first wave on T and B cell responses to a single dose of the mRNA SARS-CoV-2 vaccine BNT162b2.
(A) Nucleocapsid Abs measured by electrochemiluminescence immunoassay analyzer (ECLIA) in serum samples from HCW with (n = 25 individuals) and without (n = 26 individuals) laboratory-confirmed SARS-CoV-2 infection (Wuhan-Hu-1, during the first wave) 3 weeks after a single dose of the mRNA SARS-CoV-2 vaccine BNT162b2. (B) Magnitude of T cell response to spike protein and spike mapped epitope peptides (MEPs) in HCW with and without laboratory-confirmed SARS-CoV-2 infection (n = 23 per group). Data are shown prevaccination (16 to 18 weeks after infection) and 3 weeks after the first-dose vaccination (week 42) with line at geometric mean. (C) Proportion of HCW with (n = 23) and without (n = 23) laboratory-confirmed SARS-CoV-2 infection (during the first wave) with a T cell response to spike protein within the range of 0, 1 to 19, 20 to 79, and >80 ΔSFC/106 PBMC before and 3 weeks after first-dose vaccination. (D) Magnitude of T cell response to spike protein in HCW without a history of SARS-CoV-2 infection, plotted pairwise at 16 to 18 weeks and 42 weeks (3 weeks after first-dose vaccination). (E) Percentage of S1-specific IgG+ antibody-secreting cells (ASCs) in vaccinated HCW with (n = 23) and without (n = 22) prior SARS-CoV-2 infection and in unvaccinated HCW with (n = 12) and without (n = 5) prior infection. Line at geometric mean. (F) RBD Ab titers measured by ECLIA in serum samples from HCW with (n = 25) and without (n = 26) laboratory-confirmed SARS-CoV-2 infection following first-dose vaccination. (G) Neutralizing antibody titer (IC50) against Wuhan-Hu-1 authentic virus in HCW with (n = 24) and without (n = 20) laboratory-confirmed SARS-CoV-2 infection. Line at arithmetic mean. (H) Correlation between percentage of S1-specific ASC and magnitude of T cell response to spike protein in vaccinated HCW with (n = 21, red) and without (n = 19, blue) a history of SARS-CoV-2 infection during the first wave. (I) Correlation between percentage of S1-specific ASC and RBD Ab titer in HCW with (n = 23, red) and without (n = 23, blue) a history of SARS-CoV-2 infection. [(A), (B), (E), and (F)] Numbers of HCW in each group with detectable responses are shown. [(F) and (G)] Data are shown prevaccination (16 to 18 weeks after infection) and 3 weeks after the first-dose vaccination (week 42). [(A), (D), and (F)] Wilcoxon matched-pairs signed rank test. [(B), (C), (E), and (G)] Kruskal Wallis multiple comparison analysis of variance (ANOVA) with Dunn’s correction. [(H) and (I)] Spearman’s rank correlation. Ab, antibody; HCW, health care workers; RBD, receptor binding domain; S1, spike subunit 1; SFC, spot forming cells.
Fig. 2. Impact of vaccination and prior…
Fig. 2. Impact of vaccination and prior natural infection with SARS-CoV-2 during the first wave on T and B cell responses to the UK B.1.1.7 and South African B.1.351 variants.
(A) Neutralizing antibody (nAb) titer (IC50) against B.1.1.7 and B.1.351 authentic virus in HCW with (n = 24) and without (n = 20) laboratory-confirmed SARS-CoV-2 infection (Wuhan-Hu-1). Lines at arithmetic mean. Data are shown prevaccination (16 to 18 weeks after infection) and 3 weeks after the first-dose vaccination (week 42). (B) nAb (IC50) titers against Wuhan-Hu-1 and B.1.1.7 authentic viruses plotted pairwise by individual. (C) Percentage of Wuhan-Hu-1 S1 and S1 containing variant mutations (E484K, K417N, and N501Y) specific IgG+ antibody-secreting cells (ASCs) in vaccinated HCW with (n = 4) and without (n = 4) prior SARS-CoV-2 infection. Single-letter abbreviations for the amino acid residues are as follows: A, Ala; C, Cys; D, Asp; E, Glu; F, Phe; G, Gly; H, His; I, Ile; K, Lys; L, Leu; M, Met; N, Asn; P, Pro; Q, Gln; R, Arg; S, Ser; T, Thr; V, Val; W, Trp; and Y, Tyr. (D) Correlations between nAb (IC50) titers of Wuhan-Hu-1, B.1.1.7, or B.1.351 authentic virus and RBD Ab titer, percentage of S1-specific ASC, and magnitude of T cell response to S1 protein in vaccinated HCW with (n = 22 to 24, red) and without (n = 18 to 20, blue) a history of SARS-CoV-2 infection. (E) Magnitude of T cell response to Wuhan-Hu-1, B.1.1.7, or B.1.351 peptide pools in vaccinated HCW with (n = 23 or 18) and without (n = 23 or 18) SARS-CoV-2 infection (Wuhan-Hu-1), plotted as grouped data (median plus interquartile range) and pairwise for each individual. (F) Magnitude of T cell response to Wuhan-Hu-1 S1 protein and N501Y variant spike RBD protein in unvaccinated HCW with laboratory-confirmed SARS-CoV-2 infection (n = 14) or to Wuhan-Hu-1 and N501Y mutated peptide in vaccinated HCW with (n = 18) and without (n = 18) a history of SARS-CoV-2 infection, plotted pairwise by individual. (G) Magnitude of T cell response to Wuhan-Hu-1 or B.1.1.7 D1118H peptide in vaccinated HCW with a history of SARS-CoV-2 infection (n = 23), plotted by DRB1*0301 or DRB1*0401 status. Lines at median plus interquartile range. (H) Magnitude of T cell response to Wuhan-Hu-1 or B.1.1.7 D1118H peptide in vaccinated HCW with (n = 23) and without (n = 23) a history of SARS-CoV-2 infection, plotted pairwise by individual and with individuals carrying DRB1*0301 or DRB1*0401 alleles marked in purple. (I) Magnitude of T cell response to Wuhan-Hu-1 or B.1.351 E484K mutated peptide in vaccinated HCW with (n = 18) and without (n = 18) a history of SARS-CoV-2 infection, plotted pairwise by individual. (J) Magnitude of T cell response to Wuhan-Hu-1 (Wuh), B.1.1.7, or B.1.351 peptide pools and individual peptides in Wuhan-Hu-1 peptide immunized HLA-DRB1*04:01 transgenic mice (left-hand panel, n = 4; right-hand panel, n = 8; lines at arithmetic mean + SEM). (A) Kruskal Wallis multiple comparison ANOVA with Dunn’s correction. [(B), (C), (E) (right-hand panels), (F), (H), and (I)] Wilcoxon matched-pairs signed rank test. (D) Spearman’s rank correlation. [(E) (left-hand panels), (G), and (J)] Mann-Whitney U test. ASC, antibody-secreting cells; HCW, health care workers; RBD, receptor binding domain; S1, spike subunit 1; SFC, spot forming cells.

References

    1. Polack F. P., Thomas S. J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J. L., Pérez Marc G., Moreira E. D., Zerbini C., Bailey R., Swanson K. A., Roychoudhury S., Koury K., Li P., Kalina W. V., Cooper D., Frenck R. W. Jr.., Hammitt L. L., Türeci Ö., Nell H., Schaefer A., Ünal S., Tresnan D. B., Mather S., Dormitzer P. R., Şahin U., Jansen K. U., Gruber W. C.; C4591001 Clinical Trial Group , Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603–2615 (2020). 10.1056/NEJMoa2034577
    1. Mascola J. R., Graham B. S., Fauci A. S., SARS-CoV-2 viral variants—tackling a moving target. JAMA 325, 1261–1262 (2021). 10.1001/jama.2021.2088
    1. Altmann D. M., Boyton R. J., Beale R., Immunity to SARS-CoV-2 variants of concern. Science 371, 1103–1104 (2021). 10.1126/science.abg7404
    1. A. Rambaut, N. Loman, O. Pybus, W. Barclay, J. Barrett, A. Carabelli, T. Connor, T. Peacock, D. L. Robertson, E. Volz, on behalf of COVID-19 Genomics Consortium UK (CoG-UK), Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations, (2020); .
    1. Wang Z., Schmidt F., Weisblum Y., Muecksch F., Barnes C. O., Finkin S., Schaefer-Babajew D., Cipolla M., Gaebler C., Lieberman J. A., Oliveira T. Y., Yang Z., Abernathy M. E., Huey-Tubman K. E., Hurley A., Turroja M., West K. A., Gordon K., Millard K. G., Ramos V., Da Silva J., Xu J., Colbert R. A., Patel R., Dizon J., Unson-O’Brien C., Shimeliovich I., Gazumyan A., Caskey M., Bjorkman P. J., Casellas R., Hatziioannou T., Bieniasz P. D., Nussenzweig M. C., mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature 592, 616–622 (2021). 10.1038/s41586-021-03324-6
    1. Collier D. A., De Marco A., Ferreira I. A. T. M., Meng B., Datir R. P., Walls A. C., Kemp S. A., Bassi J., Pinto D., Silacci-Fregni C., Bianchi S., Tortorici M. A., Bowen J., Culap K., Jaconi S., Cameroni E., Snell G., Pizzuto M. S., Pellanda A. F., Garzoni C., Riva A., Elmer A., Kingston N., Graves B., McCoy L. E., Smith K. G. C., Bradley J. R., Temperton N., Ceron-Gutierrez L., Barcenas-Morales G., Harvey W., Virgin H. W., Lanzavecchia A., Piccoli L., Doffinger R., Wills M., Veesler D., Corti D., Gupta R. K.; CITIID-NIHR BioResource COVID-19 Collaboration; COVID-19 Genomics UK (COG-UK) Consortium , Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. Nature 593, 136–141 (2021). 10.1038/s41586-021-03412-7
    1. Walsh E. E., Frenck R. W. Jr.., Falsey A. R., Kitchin N., Absalon J., Gurtman A., Lockhart S., Neuzil K., Mulligan M. J., Bailey R., Swanson K. A., Li P., Koury K., Kalina W., Cooper D., Fontes-Garfias C., Shi P. Y., Türeci Ö., Tompkins K. R., Lyke K. E., Raabe V., Dormitzer P. R., Jansen K. U., Şahin U., Gruber W. C., Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N. Engl. J. Med. 383, 2439–2450 (2020). 10.1056/NEJMoa2027906
    1. Sahin U., Muik A., Derhovanessian E., Vogler I., Kranz L. M., Vormehr M., Baum A., Pascal K., Quandt J., Maurus D., Brachtendorf S., Lörks V., Sikorski J., Hilker R., Becker D., Eller A. K., Grützner J., Boesler C., Rosenbaum C., Kühnle M. C., Luxemburger U., Kemmer-Brück A., Langer D., Bexon M., Bolte S., Karikó K., Palanche T., Fischer B., Schultz A., Shi P. Y., Fontes-Garfias C., Perez J. L., Swanson K. A., Loschko J., Scully I. L., Cutler M., Kalina W., Kyratsous C. A., Cooper D., Dormitzer P. R., Jansen K. U., Türeci Ö., COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature 586, 594–599 (2020). 10.1038/s41586-020-2814-7
    1. Treibel T. A., Manisty C., Burton M., McKnight Á., Lambourne J., Augusto J. B., Couto-Parada X., Cutino-Moguel T., Noursadeghi M., Moon J. C., COVID-19: PCR screening of asymptomatic health-care workers at London hospital. Lancet 395, 1608–1610 (2020). 10.1016/S0140-6736(20)31100-4
    1. Augusto J. B., Menacho K., Andiapen M., Bowles R., Burton M., Welch S., Bhuva A. N., Seraphim A., Pade C., Joy G., Jensen M., Davies R. H., Captur G., Fontana M., Montgomery H., O’Brien B., Hingorani A. D., Cutino-Moguel T., McKnight Á., Abbass H., Alfarih M., Alldis Z., Baca G. L., Boulter A., Bracken O. V., Bullock N., Champion N., Chan C., Couto-Parada X., Dieobi-Anene K., Feehan K., Figtree G., Figtree M. C., Finlay M., Forooghi N., Gibbons J. M., Griffiths P., Hamblin M., Howes L., Itua I., Jones M., Jardim V., Kapil V., Jason Lee W.-Y., Mandadapu V., Mfuko C., Mitchelmore O., Palma S., Patel K., Petersen S. E., Piniera B., Raine R., Rapala A., Richards A., Sambile G., Couto de Sousa J., Sugimoto M., Thornton G. D., Artico J., Zahedi D., Parker R., Robathan M., Hickling L. M., Ntusi N., Semper A., Brooks T., Jones J., Tucker A., Veerapen J., Vijayakumar M., Wodehouse T., Wynne L., Treibel T. A., Noursadeghi M., Manisty C., Moon J. C., Healthcare Workers Bioresource: Study outline and baseline characteristics of a prospective healthcare worker cohort to study immune protection and pathogenesis in COVID-19. Wellcome Open Res. 5, 179 (2020). 10.12688/wellcomeopenres.16051.2
    1. Reynolds C. J., Swadling L., Gibbons J. M., Pade C., Jensen M. P., Diniz M. O., Schmidt N. M., Butler D. K., Amin O. E., Bailey S. N. L., Murray S. M., Pieper F. P., Taylor S., Jones J., Jones M., Lee W. J., Rosenheim J., Chandran A., Joy G., Di Genova C., Temperton N., Lambourne J., Cutino-Moguel T., Andiapen M., Fontana M., Smit A., Semper A., O’Brien B., Chain B., Brooks T., Manisty C., Treibel T., Moon J. C., Noursadeghi M., Altmann D. M., Maini M. K., McKnight Á., Boyton R. J.; COVIDsortium investigators; COVIDsortium immune correlates network , Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection. Sci. Immunol. 5, eabf3698 (2020). 10.1126/sciimmunol.abf3698
    1. Manisty C., Treibel T. A., Jensen M., Semper A., Joy G., Gupta R. K., Cutino-Moguel T., Andiapen M., Jones J., Taylor S., Otter A., Pade C., Gibbons J., Lee J., Bacon J., Thomas S., Moon C., Jones M., Williams D., Lambourne J., Fontana M., Altmann D. M., Boyton R., Maini M., McKnight A., Chain B., Noursadeghi M., Moon J. C., Time series analysis and mechanistic modelling of heterogeneity and sero-reversion in antibody responses to mild SARS‑CoV-2 infection. EBioMedicine 65, 103259 (2021). 10.1016/j.ebiom.2021.103259
    1. COVID-19 vaccines: Acting on the evidence. Nat. Med. 27, 183 (2021). 10.1038/s41591-021-01261-5
    1. Manisty C., Otter A. D., Treibel T. A., McKnight Á., Altmann D. M., Brooks T., Noursadeghi M., Boyton R. J., Semper A., Moon J. C., Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals. Lancet 397, 1057–1058 (2021). 10.1016/S0140-6736(21)00501-8
    1. Shen X., Tang H., McDanal C., Wagh K., Fischer W., Theiler J., Yoon H., Li D., Haynes B. F., Sanders K. O., Gnanakaran S., Hengartner N., Pajon R., Smith G., Glenn G. M., Korber B., Montefiori D. C., SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines. Cell Host Microbe 29, 529–539.e3 (2021). 10.1016/j.chom.2021.03.002
    1. Greaney A. J., Loes A. N., Crawford K. H. D., Starr T. N., Malone K. D., Chu H. Y., Bloom J. D., Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Cell Host Microbe 29, 463–476.e6 (2021). 10.1016/j.chom.2021.02.003
    1. Supasa P., Zhou D., Dejnirattisai W., Liu C., Mentzer A. J., Ginn H. M., Zhao Y., Duyvesteyn H. M. E., Nutalai R., Tuekprakhon A., Wang B., Paesen G. C., Slon-Campos J., López-Camacho C., Hallis B., Coombes N., Bewley K. R., Charlton S., Walter T. S., Barnes E., Dunachie S. J., Skelly D., Lumley S. F., Baker N., Shaik I., Humphries H. E., Godwin K., Gent N., Sienkiewicz A., Dold C., Levin R., Dong T., Pollard A. J., Knight J. C., Klenerman P., Crook D., Lambe T., Clutterbuck E., Bibi S., Flaxman A., Bittaye M., Belij-Rammerstorfer S., Gilbert S., Hall D. R., Williams M. A., Paterson N. G., James W., Carroll M. W., Fry E. E., Mongkolsapaya J., Ren J., Stuart D. I., Screaton G. R., Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. Cell 184, 2201–2211.e7 (2021). 10.1016/j.cell.2021.02.033
    1. Muik A., Wallisch A. K., Sänger B., Swanson K. A., Mühl J., Chen W., Cai H., Maurus D., Sarkar R., Türeci Ö., Dormitzer P. R., Şahin U., Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera. Science 371, 1152–1153 (2021). 10.1126/science.abg6105
    1. Reynolds C. J., Suleyman O. M., Ortega-Prieto A. M., Skelton J. K., Bonnesoeur P., Blohm A., Carregaro V., Silva J. S., James E. A., Maillère B., Dorner M., Boyton R. J., Altmann D. M., T cell immunity to Zika virus targets immunodominant epitopes that show cross-reactivity with other Flaviviruses. Sci. Rep. 8, 672 (2018). 10.1038/s41598-017-18781-1
    1. Krammer F., Srivastava K., Alshammary H., Amoako A. A., Awawda M. H., Beach K. F., Bermúdez-González M. C., Bielak D. A., Carreño J. M., Chernet R. L., Eaker L. Q., Ferreri E. D., Floda D. L., Gleason C. R., Hamburger J. Z., Jiang K., Kleiner G., Jurczyszak D., Matthews J. C., Mendez W. A., Nabeel I., Mulder L. C. F., Raskin A. J., Russo K. T., Salimbangon A. T., Saksena M., Shin A. S., Singh G., Sominsky L. A., Stadlbauer D., Wajnberg A., Simon V., Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine. N. Engl. J. Med. 384, 1372–1374 (2021). 10.1056/NEJMc2101667
    1. Bertoletti A., Tan A. T., Le Bert N., The T-cell response to SARS-CoV-2: Kinetic and quantitative aspects and the case for their protective role. Oxford Open Immunology 2, iqab006 (2021). 10.1093/oxfimm/iqab006
    1. Goel R. R., Apostolidis S. A., Painter M. M., Mathew D., Pattekar A., Kuthuru O., Gouma S., Hicks P., Meng W., Rosenfeld A. M., Dysinger S., Lundgreen K. A., Kuri-Cervantes L., Adamski S., Hicks A., Korte S., Oldridge D. A., Baxter A. E., Giles J. R., Weirick M. E., McAllister C. M., Dougherty J., Long S., D’Andrea K., Hamilton J. T., Betts M. R., Luning Prak E. T., Bates P., Hensley S. E., Greenplate A. R., Wherry E. J., Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination. Sci. Immunol. 6, eabi6950 (2021). 10.1126/sciimmunol.abi6950
    1. Public Health England, COVID-19: laboratory evaluations of serological assays, , 16 March 2021; .
    1. Peng Y., Mentzer A. J., Liu G., Yao X., Yin Z., Dong D., Dejnirattisai W., Rostron T., Supasa P., Liu C., López-Camacho C., Slon-Campos J., Zhao Y., Stuart D. I., Paesen G. C., Grimes J. M., Antson A. A., Bayfield O. W., Hawkins D. E. D. P., Ker D. S., Wang B., Turtle L., Subramaniam K., Thomson P., Zhang P., Dold C., Ratcliff J., Simmonds P., de Silva T., Sopp P., Wellington D., Rajapaksa U., Chen Y.-L., Salio M., Napolitani G., Paes W., Borrow P., Kessler B. M., Fry J. W., Schwabe N. F., Semple M. G., Baillie J. K., Moore S. C., Openshaw P. J. M., Ansari M. A., Dunachie S., Barnes E., Frater J., Kerr G., Goulder P., Lockett T., Levin R., Zhang Y., Jing R., Ho L.-P., Cornall R. J., Conlon C. P., Klenerman P., Screaton G. R., Mongkolsapaya J., McMichael A., Knight J. C., Ogg G., Dong T.; Oxford Immunology Network Covid-19 Response T cell Consortium; ISARIC4C Investigators , Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nat. Immunol. 21, 1336–1345 (2020). 10.1038/s41590-020-0782-6
    1. GISAID, Tracking of variants; .
    1. Reynisson B., Alvarez B., Paul S., Peters B., Nielsen M., NetMHCpan-4.1 and NetMHCIIpan-4.0: Improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. Nucleic Acids Res. 48, W449–W454 (2020). 10.1093/nar/gkaa379
    1. Quigley K. J., Reynolds C. J., Goudet A., Raynsford E. J., Sergeant R., Quigley A., Worgall S., Bilton D., Wilson R., Loebinger M. R., Maillere B., Altmann D. M., Boyton R. J., Chronic infection by mucoid Pseudomonas aeruginosa associated with dysregulation in T-cell immunity to outer membrane porin F. Am. J. Respir. Crit. Care Med. 191, 1250–1264 (2015). 10.1164/rccm.201411-1995OC
    1. Reynolds C., Goudet A., Jenjaroen K., Sumonwiriya M., Rinchai D., Musson J., Overbeek S., Makinde J., Quigley K., Manji J., Spink N., Yos P., Wuthiekanun V., Bancroft G., Robinson J., Lertmemongkolchai G., Dunachie S., Maillere B., Holden M., Altmann D., Boyton R., T cell immunity to the alkyl hydroperoxide reductase of Burkholderia pseudomallei: A correlate of disease outcome in acute melioidosis. J. Immunol. 194, 4814–4824 (2015). 10.4049/jimmunol.1402862

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit